Brand check
Is Pantop banned in India?
Last checked 1 October 2026
Pantop is not banned in India as of 1 Oct 2026; pantoprazole is an essential medicine, and the Pantop-D batch in the CDSCO's December 2025 alert was a spurious sample, not a regulatory action against the brand.
- Classification
- No ban or recall found in official records
- Decided by
- CDSCO / Ministry of Health and Family Welfare
- Reference
- No Section 26A notification; CDSCO monthly drug alert, Dec 2025 (published 21 Jan 2026)
- Evidence
- Government document
- Latest action
- 21 January 2026
- Last checked
- 1 October 2026
Pantoprazole 20 mg tablets (NIH drug image). Photo: Pantoprazole 20mg.jpg by NLM (Public domain). Brand names and logos belong to their owners and are used here to identify the product this entry is about. All photo credits.
CDSCO: Drug alerts (monthly NSQ / spurious lists)
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Below: Blacklisted's explanationWe organise and explain what the document says. The document above is the authority.
Key facts
- Governing authority
- CDSCO, Ministry of Health and Family Welfare
- Ban notification
- None
- Dec 2025 alert
- Pantop-D among 7 spurious samples (167 NSQ); published 21 Jan 2026
- Manufacturer
- Aristo Pharmaceuticals
- Halted combinations
- Pantoprazole + domperidone + levosulpiride / + simethicone, 11 Apr 2025 (three-drug products)
Where the claim comes from
The CDSCO's December 2025 alert, published in January 2026, named seven spurious samples including Pantop-D, three Telma-AM batches and two Chymoral Forte batches. Coverage listed the brands, and 'Pantop banned' followed. Generic pantoprazole also appears regularly among NSQ items, which adds to the impression.
Pantop is Aristo's pantoprazole brand, sold plain and as Pantop-D with domperidone. Neither is banned in India.
Pantoprazole is a proton-pump inhibitor on the National List of Essential Medicines and has never been the subject of a Section 26A notification. The two-drug pantoprazole + domperidone combination is likewise not banned; what the CDSCO halted on 11 April 2025 were three-drug versions adding levosulpiride or simethicone, licensed at state level without central approval.
The brand entered the news through the monthly quality alerts. The alert for December 2025, published on 21 January 2026, listed 167 samples not of standard quality and 7 spurious. Among the spurious samples was a Pantop-D batch, alongside three batches of Telma-AM, one of Telma 40, one of Montina-L and two of Chymoral Forte. "Spurious" in these alerts means the sample was not what its label claimed, typically a counterfeit carrying a real brand's name, and manufacturers routinely state that they did not make the batch. Generic pantoprazole tablets from various makers also appear among NSQ items in most months, because the drug is made in such volume.
None of this changes the status of Pantop. A patient with the product should compare the batch number on the strip with the one listed in the December 2025 alert; if it differs, the finding does not concern it. Buying from a licensed pharmacy with a bill is the best protection against counterfeits.
What this means for you
Pantop and Pantop-D remain licensed
The products are on sale; pantoprazole is an essential medicine.
Read the two statements side by side
CDSCO's finding is batch-specific. The company says the batch was not made by it, i.e. counterfeit. Both can be true: someone else made a fake pack with the brand's name.
Compare the batch number
The December 2025 finding concerns one batch; the alert lists it.
This is a record of official orders, not medical advice. Do not stop a prescribed medicine without asking your doctor or pharmacist.
Batches flagged in CDSCO alerts
Products whose name matches this brand or molecule in CDSCO monthly NSQ alerts. A flagged batch is a single batch; the company's response, where reported, is noted on the page above.
| Product | Batch | Manufacturer | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|---|
| Pantoprazole for Injection IP | Batch YMC-2534Mfg Sep 2025 · Exp Aug 2027 | Park PharmaceuticalsHimachal Pradesh | The sample does not conform to claim as per I.P. Addendum 2024 in respect to the Test of SterilitySterility | RDTL, GuwahatiCDSCO lab | Sep 2026 |
| Pantoprazole Sodium Gastro-resistant Tablets IP' | Batch 26KHT-0255Mfg Feb 2026 · Exp Jan 2028 | Kaalinga Health CareHimachal Pradesh | The Sample does not conform to the IP standards with respect to the tests Dissolution and Assay.Assay | DTL, ThrissurState lab | Sep 2026 |
| Pantoprazole Sodium Gastro Resistant tablets IP 40 mg | Batch OM-12884Mfg Apr 2026 · Exp Mar 2025 | D.D. Pharmaceutical Pvt. Ltd. G-1/583Rajasthan | The sample does not conform to IP with respect to the DissolutionDissolution | SDTL, GuwahatiState lab | Sep 2026 |
| Pantoprazole Gastro-resistant Tablets IP 40 mg | Batch ACTD-05Mfg Jan 2026 · Exp Dec 2027 | Nestor Pharmaceuticals LimitedHaryana | The sample received does not conform to i.p. 2022, i.p. addendum 2024 specification with respect to the test for Dissolution (acid stage) onlyDissolution | CDTL, HyderabadCDSCO lab | Sep 2026 |
| Pantoprazole Gastro Resistant Tablets IP 40 mg | Batch THE26003ALMfg Apr 2026 · Exp Mar 2028 | Hindustan Laboratories LimitedMaharashtra | Dissolution TestDissolution | SDTL, Andhra Pradesh, VijayawadaState lab | Sep 2026 |
| Pantoprazole Gastro Resistant Tablets IP 40 mg | Batch PGR018Mfg Nov 2025 · Exp Oct 2027 | RTN Pharma | Test for DissolutionDissolution | DTL, Bengaluru, KarnatakaState lab | Sep 2026 |
| Pantoprazole For Injection I.P. | Batch SPDD-001BMfg Apr 2026 · Exp Mar 2028 | Sai Pharma Pvt. LtdHaryana | The sample does not conform to I.P. in the respect of Assay.Assay | ALIGARH, Uttar PradeshState lab | Sep 2026 |
| Pantoprazole & Domperidone Tablets | Batch SRGT-25971Mfg Nov 2025 · Exp Oct 2027 | Spas RemediseHimachal Pradesh | Test for DisintegrationDisintegration | RDTL, Bellary, KarnatakaState lab | Sep 2026 |
| Pantoprazole Sodium & Domperidone Capsules | Batch SC-2085Mfg Mar 2026 · Exp Feb 2028 | Sidhdeep Biotech (P) Ltd | Assay of Pantoprazole Sodium I.P. and Domperidone I.P.Assay | SFDTL, UttarakhandState lab | Aug 2026 |
| Pantoprazole Gastro-Resistant Tablets IP 40mg | Batch APT-241290Mfg Jan 2025 · Exp Dec 2026 | ABOD PharmaceuticalsUttarakhand | The Sample does not Comply with IP requirements for the Dissolution-B Test.Dissolution | FDAL, MumbaiState lab | Aug 2026 |
| Pantoprazole For Injection I.P. 40 mg | Batch 1250095Mfg Jun 2025 · Exp May 2027 | Agron Remedies Pvt. Ltd. SarverkheraUttarakhand | The sample does not conform to IP in the respect of content of pantoprazole and particulate matter.Particulate matter | ALIGARH LABState lab | Aug 2026 |
| Pantoprazole and Domperidone Tablets | Batch T-241215Mfg Dec 2024 · Exp Nov 2026 | Medirose Drugs & Pharmaceuticals | The sample does not conform to claim with respect to above tests and The sample is not of standard quality for the reason stated under Description.Description | CDL, KolkataCDSCO lab | Jul 2026 |
| Pantoprazole and Domperidone Tablets | Batch AN-06-25Mfg Oct 2025 · Exp Sep 2027 | Anchor Pharma Pvt. LtdDaman & Diu | TEST FOR DISINTEGRATION TIMEDisintegration | DTL, DelhiState lab | Jul 2026 |
| Pantoprazole Tablets IP | Batch PEP5001Mfg Feb 2025 · Exp Jan 2027 | Finecure Pharmaceuticals Ltd. PF-5 & 6Gujarat | Dissolution testDissolution | SDT&RL, BhubaneswarState lab | Jul 2026 |
| Pantoprazole Tablets IP | Batch AGW01AKAMfg Sep 2025 · Exp Aug 2027 | Pure & Cure Healthcare Pvt. LtdUttarakhand | The sample does not conform to IP standards. It fails the test Dissolution.Dissolution | DTL, KonniState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP 40 mg | Batch SPK251470Mfg Oct 2025 · Exp Mar 2028 | Aristo Pharmaceuticals Pvt. LtdSikkim | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP 40 mg | Batch 25444650Mfg Dec 2025 · Exp May 2028 | Alkem Health ScienceSikkim | Identification - Doesn't conforms to I.P.Identification | Lucknow LabState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP | Batch AT-1952AMfg Jun 2025 · Exp May 2027 | Azot Life SciencesHimachal Pradesh | Content of Pantoprazole (84.7%)Other | Drugs Testing Laboratory, Madurai-19State lab | Jul 2026 |
| Pantoprazole Gastro-resistant and Domperidone Prolonged- released Capsules IP | Batch 25441645Mfg May 2025 · Exp Apr 2027 | Alkem Health ScienceSikkim | TESTS FOR ASSAY (CONTENT) OF PANTOPRAZOLE & UNIFORMITY OF WEIGHTAssay | DTL, DelhiState lab | Jul 2026 |
| Pantoprazole Gastro-resistant Tablets IP | Batch GD25214Mfg Dec 2025 · Exp Nov 2027 | Skymap Pharmaceuticals Pvt. LtdUttarakhand | TEST FOR DISSOLUTIONDissolution | DTL, DelhiState lab | Jul 2026 |
Ingredient records: Pantoprazole
Sources
Government documents
- Regulator
News reports
- Business Standard: CDSCO flags 7 drugs as spurious, 167 fail quality tests in Dec 2025NewsBusiness Standard · 21 January 2026
- Business Today: India halts 35 drug combinations over health risks, full listNewsBusiness Today · 17 April 2025